Please login to the form below
psoriatic arthritis
This page shows the latest psoriatic arthritis news and features for those working in and with pharma, biotech and healthcare.
AbbVie’s upadacitinib aces phase III trial
AbbVie’ s upadacitinib aces phase III trial. Arthritis drug outperformed both placebo and Humira in the study. ... even climb as high as $5bn at peak if it also shows its worth in follow-up indications like psoriatic arthritis, Crohn's disease,
Latest news
-
ViiV’s two-drug HIV combo backed by CHMP
Sandoz’Zessly, a biosimilar of J&J’s Remicade (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.
-
AbbVie reports more solid data for would-be psoriasis blockbuster
Risankizumab’s data could propel it above the $1bn threshold in psoriasis alone, according to Leerink, with additional upside if it gets approved in other indications such as psoriatic arthritis and ... data last year, and is also in pivotal trials for
-
Lilly claims another EU okay for Taltz
Eli Lilly’s new immunotherapy Taltz has picked up a second indication in Europe, with the EMA approving the IL-17 inhibitor as a second-line treatment for active psoriatic arthritis
-
Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown
The two trials - SURPASS and EXCEED - will compare interleukin-17 antagonist Cosentyx (secukinumab) against TNF blocker adalimumab in ankylosing spondylitis and psoriatic arthritis, respectively.
-
Janssen’s Tremfya cleared for European use
Meanwhile beyond the plaque psoriasis indication, Janssen is further studying Tremfya, in a phase III psoriatic arthritis development programme.
More from news
Approximately 13 fully matching, plus 104 partially matching documents found.
Latest Intelligence
-
The good, the bad and the ugly
Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic
-
Deal Watch December 2016
510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small
-
Taking a strategic approach
Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of
-
Pharma deals during July 2014
Cimzia, a pegylated antibody fragment that blocks tumour necrosis factor alpha, is currently indicated for several disorders including Crohn's disease, rheumatoid arthritis and psoriatic arthritis.
-
An eye towards the biobetter in South Korea
Emerging area. Marketed in 2007. RA = rheumatoid arthritis; AS = ankylosing spondylitis; CD = Crohn's disease; PA = psoriatic arthritis; PS = psoriasis;.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Millefeuille
Millefeuille. This story of hope charts Élodie’ s physical and mental struggles with psoriasis and psoriatic arthritis. ... For more information please visit http://bedrock-health.com/millefeuille/. Millefeuille. This story of hope charts Élodie’ s
-
Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis
Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis. Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this ... In this month’ s column we discuss how
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Programme Executive
-
Salary TBC
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Senior Medical Writer
-
Great salary and benefits
-
Scientific Director
-
Great salary and bebefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Senior Medical Writer
-
Great salary and bebefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Account Manager – Med Comms – London
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
Subscribe to our email news alerts
PMHub
McCann Complete Medical
Complete Medical delivers world-class solutions in medical communications, regulatory services, healthcare multichannel excellence, and strategic consultancy. We bring together specialist...
Latest intelligence
- No Voice, No Choice
- Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
Quick links
Infographics
